Literature DB >> 29082584

Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?

Stephen J Greene1,2, Robert J Mentz1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29082584      PMCID： PMC6457240          DOI： 10.1002/ejhf.1024

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  4 in total

Review 1.  Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Authors:  Brian Kerr; Rebabonye B Pharithi; Matthew Barrett; Carmel Halley; Joe Gallagher; Mark Ledwidge; Kenneth McDonald
Journal:  Int J Heart Fail       Date:  2021-02-25

2.  Current drug therapy for heart failure with reduced ejection fraction.

Authors:  D Berliner; M Hallbaum; J Bauersachs
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

Review 3.  Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.

Authors:  Stephen J Greene; Eric J Velazquez; Kevin J Anstrom; Eric L Eisenstein; Shelly Sapp; Shelby Morgan; Tina Harding; Vandana Sachdev; Fassil Ketema; Dong-Yun Kim; Patrice Desvigne-Nickens; Bertram Pitt; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2021-03-10       Impact factor: 12.035

Review 4.  The New Heart Failure Association Definition of Advanced Heart Failure.

Authors:  Marco Metra; Elisabetta Dinatolo; Nicolò Dasseni
Journal:  Card Fail Rev       Date:  2019-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.